Doctor uses his dyslexia to develop blueprints for cancer cure | Ep53

Get ready to hear about a true game-changer in the fight against cancer! This week, we're thrilled to introduce you to the incredible Stanley Lewis and his groundbreaking work at A28 Therapeutics.

Stanley and his team have been hard at work developing a revolutionary Targeted Lytic Peptide Platform for the Treatment of Multiple Cancer Types. And let us tell you, their lead proprietary agent, AT-101, is a real game-changer. It has already shown amazing potential as an effective cancer treatment alone, and even when used in combination with other cancer medications like immuno-oncology and chemotherapy.

Right now, A28 Therapeutics is focusing on metastatic ovarian cancer with liver metastases and hepatocellular carcinoma, and they're making incredible progress in both indications. But they need your help to finish their trials and bring this life-saving drug to market.

We can't wait for you to hear more about Stanley's story and the groundbreaking work that he and his team are doing. Trust us, this is one story that you won't want to miss!